DGAP-News: Biotest AG: Biotest AG successfully placed a Schuldschein of EUR 210 m.
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Agreement
Biotest AG: Biotest AG successfully placed a Schuldschein of EUR 210
m.
24.10.2013 / 09:00
---------------------------------------------------------------------
/
PRESS RELEASE
Biotest AG successfully placed a Schuldschein of EUR 210 m.
- Three times oversubscribed due to the significant investor demand
- Further milestone for the financing of the company growth strategy
achieved
Dreieich, October 24, 2013 - Biotest successfully placed a Schuldschein of
approx. EUR 210 m. Commerzbank Aktiengesellschaft and Landesbank
Hessen-Thüringen (Helaba) acted as bookrunners.
Biotest offered 5, 7 and 10 year tranches denominated in EUR as well as 5
year tranches denominated in USD both on a fixed and floating rate basis.
Given the strong demand from the market the transaction was significantly
oversubscribed and Biotest decided to increase the launch amount of EUR 100
m to some EUR 210 m. All tranches were fixed on the lower end of the spread
range.
The transaction has been supported by more than 70 investors, which are
mainly saving banks, commercial banks, Landesbanken and also international
banks.
The funds raised will be used for the announced capacity expansion project
as well as for general business purposes.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
24.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
235770 24.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.10.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 308850
Anzahl Zeichen: 4641
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 319 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest AG successfully placed a Schuldschein of EUR 210 m."
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
